专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07947835B2 Certain substituted amides, method of making, and method of use thereof 有权
标题翻译：某些取代的酰胺，制备方法及其使用方法
公开(公告)号：US07947835B2
公开(公告)日：2011-05-24
申请号：US11371180
申请日：2006-03-09
申请人： David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Kropf , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Douglas A. I. Pippin , Peter A. Blomgren , Douglas Gregory Stafford
发明人： David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Kropf , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Douglas A. I. Pippin , Peter A. Blomgren , Douglas Gregory Stafford
IPC分类号： C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , A61K31/501 , A61P17/06
CPC分类号： C07D213/74 , C07D241/20 , C07D241/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04
摘要： At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译：本文描述了至少一种选自式2化合物的化学实体及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物，前药及其混合物。描述了包含本发明的至少一个化学实体的药物组合物以及选自载体佐剂和赋形剂的至少一种药学上可接受的载体。描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。描述了确定样品中Btk的存在的方法。

2. 发明授权

US07405295B2 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds 有权
标题翻译：某些咪唑并[1,2-a]吡嗪-8-基胺和这种化合物抑制布鲁顿酪氨酸激酶的方法
公开(公告)号：US07405295B2
公开(公告)日：2008-07-29
申请号：US10861791
申请日：2004-06-04
申请人： Kevin S. Currie , Robert W. DeSimone , Scott A. Mitchell , Douglas A. Pippin , James W. Darrow , Xiaobing Qian , Mark Velleca , Dapeng Qian
发明人： Kevin S. Currie , Robert W. DeSimone , Scott A. Mitchell , Douglas A. Pippin , James W. Darrow , Xiaobing Qian , Mark Velleca , Dapeng Qian
IPC分类号： C07D417/00 , C07D413/00 , C07D471/00 , C07D487/00 , C07D491/00 , C07D497/00
CPC分类号： C07D487/04
摘要： Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein.Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein.Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases.
摘要翻译：本文描述式I-a化合物及其所有药学上可接受的形式。式Ia中所示的变量R 1，R 2，R 3，Z 1，Q和A 在本文中定义。本文提供了含有一种或多种式I-a化合物或这些化合物的药学上可接受的形式的药物组合物和一种或多种药学上可接受的载体，赋形剂或稀释剂。还给出了治疗患有某些对抑制酪氨酸激酶活性有响应的疾病的患者的方法。在某些实施方案中，疾病对Btk活性和/或B细胞增殖的抑制有反应。这样的方法包括向这样的患者施用一定量的有效减少疾病体征或症状的式I-a化合物。这些疾病包括癌症，自身免疫和/或炎性疾病或急性炎症反应。因此，治疗方法包括施用足够量的本文提供的化合物或盐以减少症状或减缓这些疾病的进展。

3. 发明申请

US20080139557A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF 有权
标题翻译：某些替代的制剂，制备方法及其使用方法
公开(公告)号：US20080139557A1
公开(公告)日：2008-06-12
申请号：US11853485
申请日：2007-09-11
申请人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Tony Lee , James W. Darrow , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt
发明人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Tony Lee , James W. Darrow , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt
IPC分类号： C07D401/02 , A61K31/4439 , A61K31/496 , C07D401/14 , C07D413/14 , A61K31/5377 , A61P37/00 , A61P35/00 , C12N5/00 , C12Q1/48
CPC分类号： C07D213/64 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein.Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译：本文描述了至少一种选自式1化合物的化学实体及其可药用盐，溶剂合物，螯合物，非共价复合物，前药及其混合物。描述了包含本发明的至少一个化学实体的药物组合物以及选自载体佐剂和赋形剂的至少一种药学上可接受的载体。描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。描述了确定样品中Btk的存在的方法。

4. 发明授权

US07312341B2 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof 有权
标题翻译： 6-芳基 - 咪唑并[1,2-a]吡嗪-8-基胺，其制备方法及其使用方法
公开(公告)号：US07312341B2
公开(公告)日：2007-12-25
申请号：US10658121
申请日：2003-09-09
申请人： Robert W. DeSimone , Douglas A. Pippin , James W. Darrow , Scott A. Mitchell , Kevin S. Currie
发明人： Robert W. DeSimone , Douglas A. Pippin , James W. Darrow , Scott A. Mitchell , Kevin S. Currie
IPC分类号： C07D209/00 , C07D487/02
CPC分类号： C07D487/04
摘要： A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
摘要翻译：一种新型组合物包含式1的化合物，其药学上可接受的盐，水合物，溶剂化物，晶体形式，非对映异构体，前药或其混合物。该组合物在治疗激酶介导性疾病方面特别有用。

5. 发明授权

US06919340B2 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof 失效
标题翻译：咪唑并[1,2-a]吡嗪-8-基胺，其制备方法及其使用方法
公开(公告)号：US06919340B2
公开(公告)日：2005-07-19
申请号：US10419682
申请日：2003-04-21
申请人： Kevin S. Currie , Robert W. DeSimone , Douglas A. Pippin , James W. Darrow , Scott A. Mitchell
发明人： Kevin S. Currie , Robert W. DeSimone , Douglas A. Pippin , James W. Darrow , Scott A. Mitchell
IPC分类号： A61K31/282 , A61K31/337 , A61K31/407 , A61K31/4985 , A61K31/704 , A61K31/7048 , A61K33/24 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P5/10 , A61P5/14 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/08 , A61P13/08 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , C07D487/04 , A01N43/58 , A01N43/60 , A61K31/495 , A61K31/50 , C07D471/00
CPC分类号： C07D487/04
摘要： A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
摘要翻译：一种新型组合物包含式1的化合物，其药学上可接受的盐，水合物，溶剂化物，晶体形式，非对映异构体，前药或其混合物。该组合物在治疗激酶介导性疾病方面特别有用。

6. 发明授权

US06476038B1 Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines 失效
标题翻译：氨基取代的吡唑并[1,5-a] -1,5-嘧啶和吡唑并[1,5-a] -1,3,5-三嗪
公开(公告)号：US06476038B1
公开(公告)日：2002-11-05
申请号：US09676972
申请日：2000-09-29
申请人： James W. Darrow , Stéphane De Lombaert , Charles Blum , Jennifer Tran , Mark Giangiordano , David Andrew Griffith , Philip Albert Carpino
发明人： James W. Darrow , Stéphane De Lombaert , Charles Blum , Jennifer Tran , Mark Giangiordano , David Andrew Griffith , Philip Albert Carpino
IPC分类号： C07D48704
CPC分类号： C07D487/04 , G01N2333/5755 , G01N2333/70571
摘要： Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
摘要翻译：公开了下式的化合物：其中R1，R2，R3，R4，R5，R6和X如本文所定义。这些化合物是NPY1受体的选择性调节剂。这些化合物可用于治疗许多CNS疾病，代谢紊乱和外周疾病，特别是进食障碍和高血压。还提供了治疗这种病症以及包装的药物组合物的方法。本发明的化合物也可用作NPY1受体定位的探针和作为NPY1受体结合测定中的标准物的探针。给出了在受体定位研究中使用化合物的方法。

7. 发明授权

US06291473B1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands 失效
标题翻译：氨基烷基取代的5,6,7,8-四氢-9H-吡啶并[2,3-B]吲哚和5,6,7,8-四氢-9H-嘧啶并[4,5-B]吲哚衍生物：CRF1特异性配体
公开(公告)号：US06291473B1
公开(公告)日：2001-09-18
申请号：US09283723
申请日：1999-04-01
申请人： Raymond F. Horvath , James W. Darrow , George D. Maynard
发明人： Raymond F. Horvath , James W. Darrow , George D. Maynard
IPC分类号： A61K31405
CPC分类号： C07D471/04 , C07D487/04
摘要： Disclosed are compounds of the formula: wherein Ar, R1, W, X and m are substituents as defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I.
摘要翻译：公开了下式的化合物：其中Ar，R 1，W，X和m是如本文所定义的取代基。这些化合物是CRF受体的调节剂，因此可用于治疗情感障碍，焦虑症，抑郁症，头痛，肠易激综合征，创伤性应激障碍，核上性麻痹，免疫抑制，阿尔茨海默病，胃肠道疾病，神经性厌食症或其他进食障碍，药物成瘾，药物或酒精戒断症状，炎症性疾病，心血管或心脏相关疾病，生育问题，人类免疫缺陷病毒感染，出血性压力，肥胖症，不育症，头部和脊髓创伤，癫痫，中风，溃疡，肌萎缩性侧索硬化，低血糖或疾病，其治疗可以通过拮抗CRF来实现或促进，包括但不限于由 CRF，在哺乳动物中，包括：向哺乳动物施用治疗有效量的ac 一级方程式

8. 发明授权

US08058446B2 Certain substituted amides, method of making, and method of use thereof 有权
标题翻译：某些取代的酰胺，制备方法及其使用方法
公开(公告)号：US08058446B2
公开(公告)日：2011-11-15
申请号：US11853485
申请日：2007-09-11
申请人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Tony Lee , James W. Darrow , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt
发明人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Tony Lee , James W. Darrow , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt
IPC分类号： C07D409/00 , A61K31/44
CPC分类号： C07D213/64 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译：本文描述了至少一种选自式1化合物的化学实体及其可药用盐，溶剂合物，螯合物，非共价复合物，前药及其混合物。描述了包含本发明的至少一个化学实体的药物组合物以及选自载体佐剂和赋形剂的至少一种药学上可接受的载体。描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。描述了确定样品中Btk的存在的方法。

9. 发明申请

US20100160292A1 Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors 审中-公开
标题翻译：激酶抑制剂和使用和鉴定激酶抑制剂的方法
公开(公告)号：US20100160292A1
公开(公告)日：2010-06-24
申请号：US12440695
申请日：2007-09-11
申请人： James A. Whitney , Julie Di Paolo , Mark Velleca , David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Krope , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Doughlas A.I. Pippen , Peter A. Blomgren , Doughlas Gregory Stafford
发明人： James A. Whitney , Julie Di Paolo , Mark Velleca , David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Krope , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Doughlas A.I. Pippen , Peter A. Blomgren , Doughlas Gregory Stafford
IPC分类号： A61K31/4418 , G01N33/53 , C12N9/96 , C12N5/00 , A61K31/553 , A61K31/551 , A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/4965 , A61K31/4545 , C07D403/12 , C07D413/12 , C07D241/20 , C07D401/12 , C07D213/72 , A61P37/00
CPC分类号： A61K31/00 , A61K31/44 , A61K31/4965 , A61K31/497 , A61K31/4985 , A61K31/5377 , C12Q1/485 , G01N2500/04
摘要： Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.
摘要翻译：通过抑制BTK的Y551的磷酸化抑制BTK活性的方法，提供了通过抑制BTK的Y551的磷酸化，结合BTK的化学实体和抑制复合物来抑制BTK活性来治疗患者的方法。

10. 发明授权

US07259164B2 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity 有权
标题翻译：某些取代的咪唑并[1,2-a]吡嗪，作为激酶活性的调节剂
公开(公告)号：US07259164B2
公开(公告)日：2007-08-21
申请号：US10915696
申请日：2004-08-11
申请人： Scott A. Mitchell , Robert W. DeSimone , James W. Darrow , Douglas A. Pippin , M. Diana Danca
发明人： Scott A. Mitchell , Robert W. DeSimone , James W. Darrow , Douglas A. Pippin , M. Diana Danca
IPC分类号： A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D471/00
CPC分类号： C07D487/04
摘要： Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents.A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound of Formula I under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
摘要翻译：本文提供了某些取代的咪唑并[1,2-a]吡嗪及其药学上可接受的盐。本文还提供了含有一种或多种式I化合物或这些化合物的药学上可接受的盐以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。公开了治疗患有某些对EphB4激酶调节作用的疾病和病症的患者的方法，其包括给予这样的患者一定量的有效降低疾病或病症体征或症状的式I化合物。治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂联合给药。一种用于确定样品中血管生成激酶存在或不存在的方法，包括在允许检测血管生成激酶活性，检测血管生成激酶活性水平的条件下将样品与式I化合物接触确定样品中存在或不存在血管生成激酶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式